drug_type
RELEVANT_DRUG
intervention_type
Biological - cellular vaccine
drug_description
Autologous dendritic cell (DC) vaccine made from the patient’s monocytes and loaded ex vivo with autologous glioblastoma (GBM) tumor antigens to activate tumor-specific T-cell responses.
nci_thesaurus_concept_id
C154285
nci_thesaurus_definition
A preparation of autologous dendritic cells (DCs) loaded with immunogenic tumor-associated antigens (TAAs) derived from cultured autologous glioblastoma multiforme (GBM) tumor cells, with potential immunostimulatory and antineoplastic activities. Upon administration, the autologous TAA-loaded DCs AV-GBM-1 expose the immune system to the GBM neoantigens, which results in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the autologous GBM cells leading to GBM cell lysis.
drug_mesh_term
Neoplasm Vaccines
drug_category
DC VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Autologous dendritic cells are loaded ex vivo with patient-derived glioblastoma antigens and administered to present these antigens via MHC I/II, priming tumor-specific CD8+ cytotoxic and CD4+ helper T-cell responses that drive CTL-mediated lysis of GBM cells; GM-CSF is used to enhance dendritic cell maturation and activity.
drug_name
AV-GBM-1
nct_id_drug_ref
NCT05100641